A ground-breaking new treatment for advanced pancreatic cancer has been hailed as a 'transformative' breakthrough, with a daily pill nearly doubling the average survival time for patients.
The innovative therapy, still in its experimental phase, was tested on 90 patients with advanced pancreatic cancer at the University of Texas and the University of California. The results, published in the Journal of Clinical Oncology, reveal that those taking the daily pill lived for an average of 21.6 months, significantly longer than the 10.5 months experienced by patients receiving standard chemotherapy infusions.
While more research is needed to confirm the efficacy and safety of this treatment, the study's findings are a promising indication that a more effective solution for pancreatic cancer is on the horizon. This aggressive form of cancer is notoriously difficult to treat, with a notoriously poor prognosis and limited treatment options.
The NHS's National Institute for Health and Care Excellence (NICE) recommends that patients with advanced pancreatic cancer are offered chemotherapy and/or other treatments to improve their quality of life. However, these treatments often come with significant side effects and do not significantly extend life expectancy.
The implications of this breakthrough are significant, not just for patients with pancreatic cancer, but for the NHS as a whole. If this treatment proves to be effective and safe, it could reduce the burden on healthcare services and improve patient outcomes, leading to better value for taxpayers and improved public health.